Artiva Biotherapeutics' Investigational Scalable Cell Therapies For Autoimmune Disorders, Analyst Initiate With Bullish Pitch

Quick Summary:

Artiva’s lead program, AlloNK, is an allogeneic, off-the-shelf, non-genetically modified, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity effect of monoclonal antibodies to drive B-cell depletion.

In July, Artiva Biotherapeutics, Inc.(NASDAQ:ARTV) priced its upsized initial public offering of 13.92 million shares at $12.00 per share, with gross proceeds of approximately $167.0 million.

AlloNK is currently in clinical trials for systemic lupus erythematosus, patients with or without lupus nephritis, and an investigator-initiated basket trial in multiple autoimmune indications.

---

More Pictures

---

Read Quick SummarySave Time

or

Article Details

Author / Journalist: Vandana Singh

Category: InvestingBusiness

Markets: United States

Topics: Biotech Price Target Equities Briefs Analyst Ratings Health Care Analyst Color Initiation IPOs News Expert Ideas Trading Ideas ARTV Benzinga Stories That Matter General

Source Website Secure: Yes (HTTPS)

News Sentiment: Negative

Fact Checked: Legitimate

Article Type: News Report

Published On: 2024-08-13 @ 18:14:06 (15 hours ago)

News Timezone: GMT +8:00

News Source URL: benzinga.com

Language: English

Article Length: 383 words

Reading Time: 3 minutes read

Sentences: 18 lines

Sentence Length: 22 words per sentence (average)

Platforms: Desktop Web, Mobile Web, iOS App, Android App

Copyright Owner: © Benzinga

News ID: 22069188

View Article Analysis

About Benzinga

Main Topics: InvestingBusiness

Official Website: benzinga.com

Update Frequency: 1 posts per day

Year Established: 2010

Headquarters: United States

News Last Updated: 1 days ago

Coverage Areas: United States

Ownership: Independent Company

Publication Timezone: GMT +8:00

Content Availability: Worldwide

News Language: English

RSS Feed: Available (XML)

API Access: Available (JSON, REST)

Website Security: Secure (HTTPS)

Publisher ID: #54

Publisher Details

Frequently Asked Questions